Skip to main content
Arjan Diepstra
dr.

As a hematopathologist, I work on diagnostics of all types of hematological malignancies using a comprehensive panel of different techniques. Moreover, my main research interest involves Hodgkin lymphoma, with a strong focus on interactions between tumor cells and the microenvironment. In addition, I also have a long standing interest in genetic susceptibility. My areas of expertise are: immunology, tumor cell biology, genetic association studies and molecular diagnostics in pathology. I actively participate in international (EORTC) and national (HOVON) clinical trials.

9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial
Published in: British Journal of Haematology
Access to document 10.1111/bjh.17793 document
High programmed cell death 1 ligand 1 (PD-L1) protein expression and copy number alterations (CNAs) of the corresponding genomic locus 9p24.1 in Hodgkin- and Reed-Sternberg cells (HRSC) have been shown to be associated with favourable response to anti-PD-1 checkpoint inhibition in relapsed/refractory (r/r) classical Hodgkin lymphoma (cHL). In the present study, we investigated baseline 9p24.1 status as well as PD-L1 and major histocompatibility complex (MHC) class I and II protein expression in 82 biopsies from patients with early stage unfavourable cHL treated with anti-PD-1-based first-line treatment in the...
Elena Gerhard-Hartmann, Helen Goergen, Paul J Bröckelmann, Anja Mottok, Tabea Steinmüller, Johanna Grund, Alberto Zamò, Susana Ben-Neriah, Stephanie Sasse, Sven Borchmann, Michael Fuchs, Peter Borchmann, Sarah Reinke, Andreas Engert, Johanna Veldman, Arjan Diepstra, Wolfram Klapper, Andreas Rosenwald
Interleukin-2 PET imaging in patients with metastatic melanoma before and during immune checkpoint inhibitor therapy
Published in: European Journal of Nuclear Medicine and Molecular Imaging
Access to document 10.1007/s00259-021-05407-y document
PURPOSE: Immune checkpoint inhibitors can induce a T cell-mediated anti-tumor immune response in patients with melanoma. Visualizing T cell activity using positron emission tomography (PET) might allow early insight into treatment efficacy. Activated tumor-infiltrating T cells express the high-affinity interleukin-2 receptor (IL-2R). Therefore, we performed a pilot study, using fluorine-18-labeled IL-2 ([18F]FB-IL2 PET), to evaluate whether a treatment-induced immune response can be detected. METHODS: Patients with metastatic melanoma received ~ 200 MBq [18F]FB-IL2 intravenously, followed by a PET/CT scan before and during immune checkpoint inhibitor therapy. [18F]FB-IL2 uptake...
Pim P van de Donk, Thijs T Wind, Jahlisa S Hooiveld-Noeken, Elly L van der Veen, Andor W J M Glaudemans, Arjan Diepstra, Mathilde Jalving, Elisabeth G E de Vries, Erik F J de Vries, Geke A P Hospers
Low Mutational Burden of Extra Nodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in Patients with Primary Sjogren’s Syndrome
Published in: Blood
Access to document 10.1182/blood-2021-153130
Johanna A. A. Bult, Jessica R. Placa, Erlin A. Haacke, Gwenny M. Verstappen, Frederik K. L. Spijkervet, Frans G. M. Kroese, Wouter J. Plattel, Joost S. P. Vermaat, Hendrika Bootsma, Bert Van der Vegt, Arjan Diepstra, Anke Van Den Berg, Klaas Kok, Marcel Nijland
HLA Expression in Relation to HLA Type in Classic Hodgkin Lymphoma Patients
Published in: Cancers
Access to document 10.3390/cancers13225833 document
Simple Summary:& nbsp;Classic Hodgkin lymphoma (cHL) is a B-cell malignancy with involvement of Epstein-Barr virus (EBV) in about 30% of the European population. The risk to develop cHL is strongly linked to genetic variants in the human leukocyte antigen (HLA) genomic region and to certain HLA alleles. This may be caused by the function of HLA alleles, or by genetic linkage to non-HLA genes. HLA can present EBV-derived and tumour-cell specific antigens and this may lead to anti-tumour immune responses. However, the tumour cells downregulate HLA expression in...
Geok Wee Tan, Peijia Jiang, Ilja M Nolte, Kushi Kushekhar, Rianne N Veenstra, Bouke G Hepkema, Ruth F Jarrett, Anke van den Berg, Arjan Diepstra
Case report of a clinically indolent but morphologically high-grade cutaneous mast cell tumor in an adult: Atypical cutaneous mastocytoma or mast cell sarcoma?
Published in: Journal of Cutaneous Pathology
Access to document 10.1111/cup.14088 document
We present a case of an adult male with a solitary mast cell tumor of the skin with unusual nuclear pleomorphism and mitotic activity. The tumor was excised, recurred within two years, was re-excised after four years and did not recur >six year after diagnosis. The tumor showed progressive cytonuclear atypia and a high mitotic and proliferation rate by Ki67-staining from the onset. No KIT mutations were identified in the tumor and bone marrow. Serum tryptase levels and a bone marrow aspirate and trephine biopsy were normal. Although...
Claire L W Wardle, J Marja Oldhoff, Arjan Diepstra, Peter Valent, Hans-Peter Horny, Hanneke N G Oude Elberink, Philip M Kluin, Gilles F H Diercks